Tralokinumab

eMC (Adtralza 150 mg solution for injection in pre-filled syringe). The same regimen applies to adult and adolescent patients 12 years and older. At the prescriber's discretion, every fourth week dosing may be considered for patients who achieve clear or almost clear skin after 16 weeks of treatment, although the probability of maintaining clear or almost clear skin may be lower with every fourth week dosing. Consider discontinuing treatment in patients who have shown no response after 16 weeks; some patients with an initial partial response may improve further with continued every-other-week treatment beyond 16 weeks. For patients with high body weight (>100 kg) who achieve clear or almost clear skin after 16 weeks, reducing to every fourth week might not be appropriate. Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of atopic dermatitis. Can be used with or without topical corticosteroids; topical calcineurin inhibitors may be used but should be reserved for problem areas only. For the initial 600 mg dose, four 150 mg pre-filled syringes should be administered consecutively at different injection sites within the same body area; rotate the injection site with each dose. Allow pre-filled syringes to reach room temperature for 30 minutes after removal from the refrigerator; do not shake. Missed dose: administer as soon as possible, then resume the regular schedule. Elderly: no dose adjustment recommended (limited data >75 years). Paediatric: safety and efficacy in children below 12 years have not been established — no data available.